Week 4+: Advance to 3 drops for full therapeutic effect
In addition to the FDAs scrutiny of outsourcing facilities and compounders in the GLP-1 space, the FDA has expressed concerns over the use of unapproved GLP-1 drugs for weight loss, 2 including dosing concerns with compounded semaglutide and tirzepatide products, salt forms that should not be used to compound semaglutide, use of retatrutide in compounding, and adverse events related to compounded versions of semaglutide and tirzepatide, among others
Mood Balance: Supports emotional stability and positive outlook
A.SordenS
GLP-1 weight loss medications have helped millions of patients achieve lasting results, and getting started is easier than you think
Moreover, while placebo-controlled clinical trials have found tirzepatides weight loss to be most favorable, a formal head-to-head study involving those with obesity is still in progress